Research Article

Polymorphism in LEP and LEPR May Modify Leptin Levels and Represent Risk Factors for Thyroid Cancer

Table 2

Leptin serum concentrations and LEP and LEPR SNPs genotypes compared to clinicopathological features.

Clinical pathological features Leptin serum concentration (ng/mL)LEP rs7799039 ()LEP rs2167270 ()LEPR rs1137101 ()LEPR rs1137100 ()
AAAGGGAAAGGGAAAGGGAAAGGG

Age at time of diagnosis
 ≤459.81 ± 0.58N.S.113940N.S.84839N.S.244724N.S.65203N.S.
 >4510.07 ± 0.8010332011322419301833256
Gender
 Male9.88 ± 0.60N.S.175744N.S.116346N.S.295635N.S.69376N.S.
 Female9.90 ± 0.804810271371051831
Smoking habit
 Smokers9.98 ± 0.76N.S.72012N.S.21820N.S.121711N.S.26102N.S.
 Never smoked9.82 ± 0.5813454011503823482859304
Tumour size
 <2 cm 9.99 ± 0.58N.S.143129N.S.93431N.S.213518N.S.44215N.S.
 2–4 cm 9.73 ± 0.77833256382313381642162
 >4 cm 9.95 ± 0.38115143171191391690
Extrathyroidal invasion
 Yes 9.94 ± 0.70N.S.83015N.S.53119N.S.162217N.S.32171N.S.
 No 9.87 ± 0.62163817462038293473430
Capsule
 Yes 9.80 ± 0.76N.S.81714N.S.51717N.S.111711N.S.24121N.S.
 No 9.96 ± 0.5711710120751761961
Multifocality
 Yes 9.82 ± 0.67N.S.152729N.S.93429N.S.193716N.S.44194N.S.
 No 9.88 ± 0.65734225312816272142181
Metastasis at time of diagnosis
 Present9.86 ± 0.83N.S.31617N.S.22313N.S.71813N.S.2493N.S.
 Absent9.89 ± 0.5816483211454030452160311
Stage
 I and II9.60 ± 0.74N.S.63229N.S.334320.043192921N.S.42222N.S.
 III and IV10.17 ± 0.752165414561341390
Thyroiditis
 Present9.96 ± 0.64N.S.92312N.S.42120N.S.92511N.S.28112N.S.
 Absent9.84 ± 0.39524247252220211334190
Outcome
 Disease-free 9.88 ± 0.61N.S.144328N.S.84037N.S.274018N.S.49302N.S.
 Recurrence 9.89 ± 0.824212152815923163592

N.S.: not statistically significant.